Oxford Nanopore Technologies

Oxford Nanopore Technologies

Signal active

Organization

Contact Information

Overview

Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology.

Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research.

Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education.

Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data.

Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX.

Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.

About

Industries

Biotechnology, Biopharma, Genetics, Nanotechnology, Health Diagnostics

Founded

2005

Employees

501-1000

Headquarters locations

Europe

Social

N/A

Profile Resume

Oxford Nanopore Technologies headquartered in Europe, operates in the Biotechnology, Biopharma, Genetics, Nanotechnology, Health Diagnostics sector. The company focuses on Biotechnology and has secured $624.7B in funding across 400 round(s). With a team of 501-1000 employees, Oxford Nanopore Technologies is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Oxford Nanopore Technologies, raised $19.9M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace Gordon Sanghera

Gordon Sanghera

Chief Executive Officer, Co - founder

imagePlace Clive G. Brown

Clive G. Brown

Directorships

imagePlace Spike Willcocks

Spike Willcocks

Chief BD Officer

imagePlace John Milton

John Milton

Chief Scientific Officer

imagePlace Peter Allen

Peter Allen

Chairman

imagePlace David Deamer

David Deamer

Technology Advisory Board

Funding Rounds

Funding rounds

20

Investors

2

Lead Investors

0

Total Funding Amount

$1561.7M

Details

5

Oxford Nanopore Technologies has raised a total of $1561.7M in funding over 5 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2005Seed891.5K
2006Early Stage Venture14.5M
2010Late Stage Venture27.7M
2008Early Stage Venture19.9M

Investors

Oxford Nanopore Technologies is funded by 49 investors.

Investor NameLead InvestorFunding RoundPartners
Oxford Nanopore Technologies-FUNDING ROUND - Oxford Nanopore Technologies14.5M
Woodford Investment Management-FUNDING ROUND - Woodford Investment Management14.5M
Oxford Nanopore Technologies-FUNDING ROUND - Oxford Nanopore Technologies14.5M
QBN Capital-FUNDING ROUND - QBN Capital14.5M

Recent Activity

There is no recent news or activity for this profile.